Dr. Fouad Kandeel is the Principal Investigator on the islet transplantation trial to determine the safety and efficacy of islet cell transplantation as a treatment for patients with type 1 diabetes. In addition, Dr. Kandeel has recently concluded a clinical project to identify genes related to the development of type 2 diabetes and cardiovascular disease in the Hispanic population. He also continues to oversee the Diabetes and Cardiovascular Risk Reduction Program, which he established several years ago at City of Hope. Due to his strong background in endocrine tumors and thyroid cancer, Dr. Kandeel participates in the development of the national guidelines for the management of neuroendocrine tumors and thyroid cancer.
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.